Trial Profile
A multicenter, open-label, 24-week pilot study to evaluate the safety and efficacy of indinavir sulfate 800 mg b.i.d. [twice daily] in combination with ritonavir 100 mg/d4T [stavudine]/3TC [lamivudine] b.i.d. in HIV-infected individuals
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Indinavir (Primary) ; Lamivudine/stavudine (Primary) ; Ritonavir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 21 Oct 2005 New trial record.